Clinical Benefit From a Combination of Brigatinib and Camrelizumab in Sarcomatoid Transformation of ALK-Rearranged Squamous Cell Lung Cancer Resistant to Crizotinib

Detalles Bibliográficos
Autores principales: Jiang, Wei, Guan, Ruting, Shao, Yang W., Wang, Bo, Wang, Yina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474269/
https://www.ncbi.nlm.nih.gov/pubmed/34589922
http://dx.doi.org/10.1016/j.jtocrr.2020.100009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474269/
https://www.ncbi.nlm.nih.gov/pubmed/34589922
http://dx.doi.org/10.1016/j.jtocrr.2020.100009

Ejemplares similares